[ad_1]
Belgian patients with Spinal Muscular Atrophy (5q-SMA) will be reimbursed on September 1 for Spinraza (nusinersen), an orphan drug used in the treatment of this rare condition, says Thursday the Minister of Health , Maggie De Block, in a statement.
This myopathy occurs in one birth over 6,000 to 10,000. Because of the short life expectancy, the total number of children with ADS is limited in Belgium.
Until recently, no treatment was available in Europe but this situation changed last year with the registration of Spinraza with the European Medicines Agency. This treatment improves the state of health and increases the life expectancy of SMA-5q patients.
"I am very happy that we can repay this orphan drug," said Minister De Block, pointing out that this reimbursement was the result of a joint negotiation with the Netherlands and the producer of the drug under the BeNeLuxA initiative
The confidential agreement that Belgium and the Netherlands concluded with the firm plans a temporary reimbursement of Spinraza until the end of December 2020. At the end of the term of the agreement, the Inami Drug Reimbursement Board will review the reimbursement on the basis of the data collected.
Source link
